EIKN
Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. insider trading
Eikon Therapeutics, Inc. is on this site because an insider bought its stock on the open market in the last 30 days. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
From SEC filings · last 30 days
Recent EIKN insider transactions
The filing store could not be read just now — this page tries again on its next refresh. The filings themselves are on SEC EDGAR.
SEC Form 4 data, Q3 2024 to Q2 2026
EIKN insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 4 insiders traded EIKN on the open market: 6 purchases worth $43.6M and 0 sales. In the last four quarters alone: 6 purchases ($43.6M) and 0 sales, by 4 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | +$43.6M6 buys | — | |
| Q4 2025 | — | — | |
| Q3 2025 | — | — | |
| Q2 2025 | — | — | |
| Q1 2025 | — | — | |
| Q4 2024 | — | — | |
| Q3 2024 | — | — |
- Largest purchase
- +$25.9M of EIKN by Column Group Opportunity III, LP (10% Owner) on Feb 06, 2026.
Open-market transactions through Jun 30, 2026most recent first
Column Group Opportunity III, LP
10% Owner
+$25.9M
Feb 06, 2026
1,437,323 sh · $18.00
Column Group Opportunity III, LP
10% Owner
+$11.4M
Feb 06, 2026
630,881 sh · $18.00
Column Group Opportunity III, LP
10% Owner
+$892K
Feb 06, 2026
49,556 sh · $18.00
Wolfe Josh
Director · 10% Owner
+$2.5M
Feb 04, 2026
138,888 sh · $18.00
Frazier Kenneth C
Director
+$2M
Feb 04, 2026
111,111 sh · $18.00
Foresite Capital Opportunity Management V, LLC
10% Owner
+$1M
Feb 04, 2026
55,555 sh · $18.00
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 06, 2026 | Column Group Opportunity III, LP10% Owner | 1,437,323 | $18.00 | +$25.9M |
| Feb 06, 2026 | Column Group Opportunity III, LP10% Owner | 630,881 | $18.00 | +$11.4M |
| Feb 06, 2026 | Column Group Opportunity III, LP10% Owner | 49,556 | $18.00 | +$892K |
| Feb 04, 2026 | Wolfe JoshDirector · 10% Owner | 138,888 | $18.00 | +$2.5M |
| Feb 04, 2026 | Frazier Kenneth CDirector | 111,111 | $18.00 | +$2M |
| Feb 04, 2026 | Foresite Capital Opportunity Management V, LLC10% Owner | 55,555 | $18.00 | +$1M |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check EIKN — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Eikon Therapeutics, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- How much EIKN stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 4 Eikon Therapeutics, Inc. insiders made 6 open-market purchases worth $43.6M and no sales. In the four quarters to Jun 30, 2026: 6 purchases ($43.6M) and no sales. The largest purchase was Column Group Opportunity III, LP buying $25.9M on Feb 06, 2026.
- Where does EIKN insider trading data come from?
- From the Form 4 filings Eikon Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.